144 related articles for article (PubMed ID: 25394023)
21. Validation of the D: A: D Chronic Kidney Disease Risk Score Model Among People Living With HIV in the Asia-Pacific.
Han WM; Bijker R; Chandrasekaran E; Pujari S; Ng OT; Ly PS; Lee MP; Van Nguyen K; Chan YJ; Do CD; Choi JY; Chaiwarith R; Merati TP; Kiertiburanakul S; Azwa I; Khusuwan S; Zhang F; Gani YM; Tanuma J; Sangle S; Ditangco R; Yunihastuti E; Ross J; Avihingsanon A;
J Acquir Immune Defic Syndr; 2020 Dec; 85(4):489-497. PubMed ID: 33136750
[TBL] [Abstract][Full Text] [Related]
22. Validation of the D:A:D chronic kidney disease risk score in people living with HIV: the IeDEA West Africa Cohort Collaboration.
Poda A; Kabore NF; Malateste K; De Rekeneire N; Semde A; Bikinga Y; Patassi A; Chenal H; Messou E; Dabis F; Ekouevi DK; Jaquet A; Cournil A
HIV Med; 2021 Feb; 22(2):113-121. PubMed ID: 33145918
[TBL] [Abstract][Full Text] [Related]
23. Influence of hepatitis C virus co-infection and hepatitis C virus treatment on risk of chronic kidney disease in HIV-positive persons.
Mocroft A; Ryom L; Oprea C; Li Q; Rauch A; Boesecke C; Uzdaviniene V; Sedlacek D; Llibre JM; Lacombe K; Nielsen LN; Florence E; Aho I; Chkhartishvili N; Szlavik J; Dragovic G; Leen C; Sambatakou H; Staub T; Laguno M; Elinav H; Tomažič J; Peters L;
AIDS; 2020 Aug; 34(10):1485-1495. PubMed ID: 32675562
[TBL] [Abstract][Full Text] [Related]
24. Use of Contemporary Protease Inhibitors and Risk of Incident Chronic Kidney Disease in Persons With Human Immunodeficiency Virus: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study.
Ryom L; Dilling Lundgren J; Reiss P; Kirk O; Law M; Ross M; Morlat P; Andreas Fux C; Fontas E; De Wit S; D'Arminio Monforte A; El-Sadr W; Phillips A; Ingrid Hatleberg C; Sabin C; Mocroft A;
J Infect Dis; 2019 Oct; 220(10):1629-1634. PubMed ID: 31504669
[TBL] [Abstract][Full Text] [Related]
25. Comparison of body composition changes between atazanavir/ritonavir and lopinavir/ritonavir each in combination with tenofovir/emtricitabine in antiretroviral-naïve patients with HIV-1 infection.
Moyle GJ; Hardy H; Farajallah A; DeGrosky M; McGrath D
Clin Drug Investig; 2014 Apr; 34(4):287-96. PubMed ID: 24557728
[TBL] [Abstract][Full Text] [Related]
26. Impact of switching from lopinavir/ritonavir to boosted and un-boosted atazanavir on glucose metabolism: the ATAzanavir & GLUcose metabolism (ATAGLU) study.
d'Ettorre G; Ceccarelli G; Zaccarelli M; Ascoli-Bartoli T; Bianchi L; Bellelli V; De Girolamo G; Serafino S; Giustini N; Mastroianni CM; Vullo V
Int J STD AIDS; 2016 Jul; 27(8):638-43. PubMed ID: 26068963
[TBL] [Abstract][Full Text] [Related]
27. Cost-utility analysis of lopinavir/ritonavir versus atazanavir + ritonavir administered as first-line therapy for the treatment of HIV infection in Italy: from randomised trial to real world.
Foglia E; Bonfanti P; Rizzardini G; Bonizzoni E; Restelli U; Ricci E; Porazzi E; Scolari F; Croce D
PLoS One; 2013; 8(2):e57777. PubMed ID: 23460905
[TBL] [Abstract][Full Text] [Related]
28. Cardiovascular disease (CVD) and chronic kidney disease (CKD) event rates in HIV-positive persons at high predicted CVD and CKD risk: A prospective analysis of the D:A:D observational study.
Boyd MA; Mocroft A; Ryom L; Monforte AD; Sabin C; El-Sadr WM; Hatleberg CI; De Wit S; Weber R; Fontas E; Phillips A; Bonnet F; Reiss P; Lundgren J; Law M
PLoS Med; 2017 Nov; 14(11):e1002424. PubMed ID: 29112958
[TBL] [Abstract][Full Text] [Related]
29. Prevalence of chronic kidney disease among HIV-1-infected patients receiving a combination antiretroviral therapy.
Calza L; Sachs M; Colangeli V; Borderi M; Granozzi B; Malosso P; Comai G; Corradetti V; La Manna G; Viale P
Clin Exp Nephrol; 2019 Nov; 23(11):1272-1279. PubMed ID: 31327092
[TBL] [Abstract][Full Text] [Related]
30. Serious clinical events in HIV-positive persons with chronic kidney disease.
Ryom L; Lundgren JD; Law M; Kirk O; El-Sadr W; Bonnet F; Weber R; Fontas E; Monforte AD; Phillips A; Reiss P; de Wit S; Hatleberg CI; Sabin C; Mocroft A;
AIDS; 2019 Nov; 33(14):2173-2188. PubMed ID: 31385862
[TBL] [Abstract][Full Text] [Related]
31. Risk factors for chronic kidney disease in a large cohort of HIV-1 infected individuals initiating antiretroviral therapy in routine care.
Kalayjian RC; Lau B; Mechekano RN; Crane HM; Rodriguez B; Salata RA; Krishnasami Z; Willig JH; Martin JN; Moore RD; Eron JJ; Kitahata MM
AIDS; 2012 Sep; 26(15):1907-15. PubMed ID: 22824630
[TBL] [Abstract][Full Text] [Related]
32. Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: a multicenter analysis.
Zaccarelli M; Fabbiani M; Pinnetti C; Borghi V; Giannetti A; Sterrantino G; Lorenzini P; Latini A; Loiacono L; Colafigli M; Ammassari A; D'Ettorre G; Plazzi M; Di Giambenedetto S; Antinori A
J Int AIDS Soc; 2014; 17(4 Suppl 3):19802. PubMed ID: 25397546
[TBL] [Abstract][Full Text] [Related]
33. Cost effectiveness of lopinavir/ritonavir compared with atazanavir plus ritonavir in antiretroviral-experienced patients in the US.
Simpson KN; Jones WJ; Rajagopalan R; Dietz B
Clin Drug Investig; 2007; 27(7):443-52. PubMed ID: 17563124
[TBL] [Abstract][Full Text] [Related]
34. High incidence of renal stones among HIV-infected patients on ritonavir-boosted atazanavir than in those receiving other protease inhibitor-containing antiretroviral therapy.
Hamada Y; Nishijima T; Watanabe K; Komatsu H; Tsukada K; Teruya K; Gatanaga H; Kikuchi Y; Oka S
Clin Infect Dis; 2012 Nov; 55(9):1262-9. PubMed ID: 22820542
[TBL] [Abstract][Full Text] [Related]
35. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures.
Johnson M; Grinsztejn B; Rodriguez C; Coco J; DeJesus E; Lazzarin A; Lichtenstein K; Rightmire A; Sankoh S; Wilber R
AIDS; 2005 Apr; 19(7):685-94. PubMed ID: 15821394
[TBL] [Abstract][Full Text] [Related]
36. An overview of tenofovir and renal disease for the HIV-treating clinician.
Venter WDF; Fabian J; Feldman C
South Afr J HIV Med; 2018; 19(1):817. PubMed ID: 30167339
[TBL] [Abstract][Full Text] [Related]
37. Determinants of incident chronic kidney disease and progression in a cohort of HIV-infected persons with unrestricted access to health care.
Ganesan A; Krantz EM; Huppler Hullsiek K; Riddle MS; Weintrob AC; Lalani T; Okulicz JF; Landrum M; Agan B; Whitman TJ; Ross MJ; Crum-Cianflone NF;
HIV Med; 2013 Feb; 14(2):65-76. PubMed ID: 22808988
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of "unboosting" atazanavir in a randomized controlled trial among HIV-infected patients receiving tenofovir DF.
Harris M; Ganase B; Watson B; Hull MW; Guillemi SA; Zhang W; Saeedi R; Harrigan PR
HIV Clin Trials; 2017 Jan; 18(1):39-47. PubMed ID: 28067119
[TBL] [Abstract][Full Text] [Related]
39. Brief Report: Tenofovir-Associated Nephrotoxicity Among a US National Historical Cohort of HIV-Infected Veterans: Risk Modification by Concomitant Antiretrovirals.
LaFleur J; Bress AP; Esker S; Knippenberg K; Crook J; Nyman H; Bedimo R; Tebas P; Rosenblatt L
J Acquir Immune Defic Syndr; 2018 Mar; 77(3):325-330. PubMed ID: 29210830
[TBL] [Abstract][Full Text] [Related]
40. Role of systemic inflammation scores for prediction of clinical outcomes in patients treated with atazanavir not boosted by ritonavir in the Italian MASTER cohort.
Postorino MC; Prosperi M; Focà E; Quiros-Roldan E; Di Filippo E; Maggiolo F; Borghetti A; Ladisa N; Di Pietro M; Gori A; Sighinolfi L; Pan A; Mazzini N; Torti C
BMC Infect Dis; 2017 Mar; 17(1):212. PubMed ID: 28298195
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
